Pandemic Response Lessons for Biopharma Companies

November 4, 2020
Pharmaceutical Technology Editors

Biopharma can apply new manufacturing practices adopted during the COVID-19 pandemic to enhance bioprocessing.

How have biopharma companies responded and adjusted to pandemic issues? What lessons learned under fire may lead to more effective and efficient bioprocessing practices going forward? Eric Langer, managing partner, BioPlan Associates, Inc., shares research and expert insight in Delivering on the Promise: Overcoming Biopharma Development and Manufacturing Challenges, during the 2020 Bio/Pharma Virtual Congress on Nov. 11, 2020, at 10 am EST.

The online Bio/Pharma Virtual Congress features a full day of panel discussions organized and moderated by the editors of Pharmaceutical Technology and BioPharm International magazines, sponsored technical sessions, a Virtual Exhibit Hall where visitors can chat in real-time with exhibitors, technical posters, and networking opportunities.

The Delivering on the Promise session is part of the Drug Dosage Forms track at the Virtual Congress; other topics include strategies to move drugs from discovery to development and genotoxic impurities.

Registration for the day-long event (8:30 am–4 pm EST) is free to professionals involved in the development and manufacture of bio/pharmaceuticals.

Insight on the pandemic, Bio/Pharma’s response, and more

The COVID-19 pandemic’s impact on bio/pharmaceutical development and manufacturing, availability of crucial supplies, maintaining GMP compliance, and remote monitoring of manufacturing processes are other topics that will be discussed by industry experts during the 2020 Bio/Pharma Virtual Congress. Download the agenda (PDF).

During a keynote panel discussion—Bio/Pharma Industry—Beyond Politics and the Pandemic—on Nov 11, 2020, 9 am EST, representatives from industry organizations, will discuss bio/pharma’s response to the pandemic and the corresponding scrutiny and political pressure, as well as the short-, medium-, and long-term implications for bio/pharma development and manufacturing.

Manufacturing Trends
New technologies, such as artificial intelligence and machine learning, are being employed by bio/pharma manufacturers to collect and analyze large amounts of process data in real-time.

An expert panel will discuss how this technology can be employed to optimize bio/pharma manufacturing and predictive maintenance during the Editors’ Series session, Technology Advances in Process Operations on Nov. 11, 2020, 11:30 am EST.

Formulation Trends
An expert panel will discuss the characterization of excipient components, understanding regulatory and compendial implications of excipient composition, the global supply chain, effective quality programs and prospects for preapproval of novel excipients. The Editors’ Series session, Excipients Update: Formulation, Supply and Quality, is scheduled for Nov. 11, 2020, 1:30 pm EST.

Bio/Pharma Industry Challenges
A panel discussion—A “New Normal” for Quality Practices—will reviewquality and regulatory challenges amid the pandemic, focusing on new technologies such as remote monitoring, risk-based quality management, Annex 1 changes, and lessons learned going forward. The panel, part of the Bio/Pharma Industry Challenges track, is scheduled for Nov. 11, 2020, 1:30 pm.

To learn more about the 2020 Bio/Pharma Virtual Congress, download the agenda.